Appili Therapeutics Inc. (TSX: APLI) has announced it will voluntarily delist its Class A common shares from the Toronto Stock Exchange and transfer the listing to the NEX Board of the TSX Venture Exchange, effective October 5, 2026. The move follows the company's failure to meet TSX continued listing requirements. Shares will be delisted from the TSX at the close of markets on October 2, 2026, and will begin trading on the NEX under the symbol "APLI.H" on October 5, 2026. The development is a significant status change for investors holding the Halifax-based biopharmaceutical company's shares.

Key Points

  • Appili Therapeutics Inc. (TSX: APLI / OTC Pink: APLIF) is transferring to the NEX Board of the TSX Venture Exchange
  • The company applied for voluntary delisting from the TSX after failing to meet continued listing requirements
  • TSX delisting takes effect at market close on October 2, 2026; NEX trading begins October 5, 2026 under symbol "APLI.H"
  • Investors may be watching how the exchange transfer affects liquidity and the company's ongoing drug development pipeline

Why Appili Therapeutics Is Leaving the TSX

Appili Therapeutics has applied to voluntarily delist from the TSX after failing to satisfy the exchange's continued listing requirements. The company's announcement states that the TSX is unlikely to be satisfied that the deficiencies will be cured within the prescribed period. As a result, shareholder approval of the delisting is not required under TSX policies. No action is required from shareholders in connection with the transfer. The company confirmed there is no change to its corporate name, no change to its CUSIP number, and no consolidation of capital associated with this transition.

Trading Symbol Change and NEX Board Mechanics

Once the transition takes effect, Appili's trading symbol will change from "APLI" to "APLI.H" on the NEX Board, with the ".H" extension used to differentiate NEX-listed securities from those on the broader TSX market. The NEX is a separate board of the TSX Venture Exchange designed for listed companies with no ongoing business or that have failed to maintain a senior exchange's continued listing standards. The OTC Pink market symbol, APLIF, was not addressed in the announcement regarding any change resulting from the transition.

Appili's Infectious Disease Pipeline Remains Active

Despite the exchange transfer, Appili Therapeutics describes itself as actively advancing a portfolio of anti-infective therapies. The company's pipeline includes an FDA-approved ready-made suspension of metronidazole targeting antimicrobial-resistant infections, a vaccine candidate aimed at preventing tularemia — a serious biological weapon threat — and a topical antiparasitic for cutaneous leishmaniasis. The company did not disclose updated timelines, clinical milestones, or financing arrangements in this announcement. The immediate share price impact of the NEX transfer was not clear from available public information.